Exelixis | EXEL - Ativos





Ativos Alterar Data
Acadia Pharmaceuticals USD 1.74B 137.67M 2026-06
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Akebia Therapeutics USD 349.66M 12.86M 2026-06
Amgen USD 95.64B 3.14B 2026-06
AstraZeneca USD 115.83B 1.82B 2026-06
Bayer EUR 107.29B 659M 2026-06
BioMarin Pharmaceutical USD 11.72B 3.13B 2026-06
Bristol-Myers Squibb USD 88.77B 1.14B 2026-09
Cytokinetics USD 1.92B 651.07M 2026-06
Eisai JPY 1.56T 108.98B 2026-06
Eli Lilly USD 148.07B 5.79B 2026-09
Exelixis USD 2.49B 99.36M 2026-06
Genmab DKK 12.52B 139M 2026-06
Glaxosmithkline GBP 62.87B 19.47B 2026-03
Incyte USD 7.29B 585.39M 2026-09
Ionis Pharmaceuticals USD 2.99B 455.5M 2026-06
MacroGenics USD 345.41M 127.54M 2026-06
Merck USD 129.8B 1.12B 2026-06
Moderna USD 10.96B 527M 2026-06
Nektar Therapeutics USD 763.27M 482.86M 2026-03
Neurocrine Biosciences USD 5.36B 452.9M 2026-06
Novartis USD 122.03B 3.5B 2026-06
Pfizer USD 201.13B 6.49B 2026-06
Puma Biotechnology USD 202.86M 7.95M 2025-09
Sanofi EUR 128.02B 1.22B 2026-03
Takeda JPY 15.27T 391.77B 2026-09
Ultragenyx Pharmaceutical USD 1.26B 32M 2026-06
Xencor USD 724.96M 11.89M 2026-06